Age: 48 · Location: Belgium · Frame: operator (Platform-CEO) · Judge tier: 1c · Judge Focus-44 rank: 8
CONTESTED — kit: left Palex Apr-2026, on market via FH Impact Management; Lin: Duomed CEO IN_SEAT + UK-CH officer of Duomed Holding UK Ltd 13641088
_Company: FH Impact Management (BE 0797340691) / Duomed Holding UK Ltd (contested)._
McKinsey → 13yr Baxter (VP Strategy Europe, GM Benelux/France) → Duomed COO / CEO through the Palex sale and three integrations.
McKinsey → 13yr Baxter (VP Strategy Europe, GM Benelux/France) → Duomed COO then CEO through the Palex sale and integration.
Lin 44-walk: IN_SEAT confirmed Duomed CEO Sep-2026. Kit "Palex VP N+C Europe end-date Apr-2026" NOT SUPPORTED.
IN_SEAT — Duomed CEO within Palex Group Sep-2026 (Lin 44-walk CONFIRMED). Kit "left Palex Apr-2026" NOT SUPPORTED. Belgian-based; INSEAD MBA + MSc EE
Outreach window: Defer pending Trawl resolution
Same as vdL — G Square or Houlihan Lokey; direct via FH Impact Management as first-touch; pair with vdL
operator (Platform-CEO) · Diploma / Halma (specialist distribution pan-European) · L4 bracket ADJACENT · L1=3 L2=4 L4=3 L5=2 L6=5
Path to seat: professional_platform_ceo
Data gap: Availability status contested; Palex covenant terms; UK Holding directorship residual vs operational
Data gap: L6 evidence-only rescore: FH Impact Management (personal mgmt co) = open-market signal; post-Palex Apr-2026 (kit reading)